• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Exp Immunol . Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infect

tetano

Editor, Senior Moderator
Clin Exp Immunol


. 2023 Jun 14;uxad066.
doi: 10.1093/cei/uxad066. Online ahead of print. Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals

Pradeep D Pushpakumara[SUP] 1 [/SUP], Chandima Jeewandara[SUP] 1 [/SUP], Farha Bary[SUP] 1 [/SUP], Deshan Madushanka[SUP] 1 [/SUP], Lahiru Perera[SUP] 1 [/SUP], Inoka Sepali Aberathna[SUP] 1 [/SUP], Thashmi Nimasha[SUP] 1 [/SUP], Jeewantha Jayamali[SUP] 1 [/SUP], Thushali Ranasinghe[SUP] 1 [/SUP], Heshan Kuruppu[SUP] 1 [/SUP], Saubhagya Danasekara[SUP] 1 [/SUP], Ananda Wijewickrama[SUP] 2 [/SUP], Graham S Ogg[SUP] 3 [/SUP], Gathsaurie Neelika Malavige[SUP] 1 3 [/SUP]



Affiliations
Abstract

As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine.Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.

Keywords: ELISA; SARS-COv-2; Sinopharm; conservation; immunodominant; nucleocapsid protein; overlapping peptides; sarbecoviruses; variants.

 
Back
Top Bottom